Mild cognitive impairment: new neuropsychological and pharmacological target.
Mild cognitive impairment (MCI) is increasingly being conceptualized in the literature as a cognitive disturbance representing a transitional phase between normal aging and dementia. The operational definitions of MCI provide an opportunity for neuropsychologists to detect subtle deficit and monitor cognitive status sequentially in order to determine rate and degree of progression. More importantly, clinical and neuropsychological studies are needed that can better characterize which MCI patients are at greatest risk for conversion to dementia. Preliminary data has also designated MCI as a potential indicator for initiation of pharmacotherapy, with the objective of decelerating rate of progression to dementia. Current criteria and clinical issues related to MCI are discussed, with the objective of better familiarizing clinicians with this syndrome and fostering ongoing investigations.
Rivas-Vazquez
Rafael A
RA
Neurologic Center of South Florida, Psy. D. 8940 N. Kendall Drive, Suite 802-E, Miami, FL 33176, USA. rafrv@bellsouth.net
Mendez
Cecilia
C
Rey
Gustavo J
GJ
Carrazana
Enrique J
EJ
D003072:Cognition Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology*; D006801:Humans; D012720:Severity of Illness Index